|
(I-Newswire) September 11, 2010 - Tampa, FL – For Quantum Immunologics and its veteran CEO Chuck Broes, 2010 is turning out to be a spectacular year. While capital is always a focus for early stage companies, Chuck Broes reported that there was exceptional response to Quantum Immunologics’ most current round of private placement funding coupled with the company’s warrant program. Heading into the fall the company is preparing for a focused road show for the investment community as well as notice anticipated in October relating to the level of funding allocated through the Qualifying Therapeutic Discovery Project Grants (QTDP) program.
Those who know Chuck Broes say that a key to his successes along the way is the solid bridge he builds between the company and those who have entrusted him with early stage capital. Frequent communication in the form of newsletters to stakeholders would be sufficient for most companies at this stage of growth. Chuck Broes leads this venture with even greater transparency and interaction with its investors.
The Quantum Immunologics management team was recently joined by members of the Shareholder Advisory Committee (SAC) for an in-depth review of the company’s daily operations. With reports both provided and discussed, Chuck Broes encouraged each shareholder to participate as a member of the SAC forum and to consider the SAC’s feedback and observations. It takes a quiet confidence to openly discuss the technical details of a company such as Quantum Immunologics. Chuck Broes and his team have a long history with this type of approach and it has served them well through several previous ventures.
This openness and transparency is, in large part, what has attracted the company’s slate of qualified independent board members, legal, accounting and audit firms as well as compensation, governance and nominating committee chairs. “The caliber of talent brought in at such an early stage of growth is both gratifying and humbling,” acknowledges Chuck Broes.
When Chuck Broes presents the company, one of the core messages he communicates is that a key business objective focuses on intellectual properties. As patent filings accumulate, they constitute the company’s primary business assets. This strategy seems to ring true as Chuck Broes speaks to the investment community.
Clearly Chuck Broes understands that as the market for initial public offerings of public equities is reenergized, investors are looking for value as well as the opportunity to develop and protect proprietary technology assets that can be leveraged and quickly scaled and brought to market. Quantum Immunologics is uniquely positioned within the scientific and business communities to become a leader in the treatment pathway for new therapies and diagnostic applications for various potential OFA applications.
Chuck Broes has assembled the right team at the right time and Quantum Immunologics is in the initial stages of conducting the necessary pre-clinical work for these technologies at the University of Michigan in Ann Arbor. This research involves testing various tumor cells to determine levels of OFA expression. In the company’s ongoing dialogue with the investment community, Chuck Broes has taken what could be a daunting presentation of pharmaceutical data and deconstructing the information so that the investment community catches the same vision for growth that Chuck Broes and his team possess.
Presented with the recent opportunity to paint a vision of where the company could be in the near future, Chuck Broes summed it up by sharing that, given sufficient funding, Quantum Immunologics’ science team will continue to focus on developing cancer therapies that could change the oncology field and promote a paradigm shift in the way cancer is treated. A lofty aspiration for some, but Chuck Broes has built his life as being a visionary and seeing things as they could be rather thaen as they are.
Chuck Broes is CEO of Quantum Immunologics, LLC, a Tampa, Florida-based company involved in immunotherapy technologies. He can be reached at 813-849-7885.
About Quantum Immunologics:
Chuck Broes is a business and healthcare visionary whose career spans over 45 years in domestic and foreign markets. In the past, Chuck Broes has specialized in the areas of incubation, start-ups, mergers and acquisitions, corporate turn-arounds and roll-ups. Chuck Broes has served in various executive roles including Chief Executive Officer, Chief Financial Officer and Chief Operating Officer.
Chuck Broes began his unique career with Health Industries (Jack LaLanne European Health Spas) from its founding to becoming a national chain of over one hundred locations, then going public and later being sold to a Fortune 500 company. This positioned Chuck Broes to serve in key leadership roles within the healthcare and pharmaceutical industries working with regulatory issues involving the FDA, ISO and CE marking and EDI. Chuck Broes was involved intimately as part of the senior management team at Wellmark Corporation, a pioneer company in healthcare clearinghouse services and ANSI X12 standards, which became a subsidiary of Primark Corporation, a NYSE Company.
Later, Chuck Broes founded EliteCorp International, Inc. and served as its Chief Executive Officer. In that capacity Chuck Broes’ business experience has included the facilitation of public companies, acquisitions, mergers, strategic alliances, IPOs and turnarounds. Associated projects for Chuck Broes have ranged from concept to development and production, including the integration of national data communication networks, facilities management, and healthcare system technologies.
Chuck Broes has served as a member of the Ethics Committee of the Moffitt Cancer Center in Tampa, Florida for fifteen years. In 2008, Chuck Broes turned his full attention to Quantum Immunologics, Inc., which he helped found and where he currently serves as CEO. Chuck Broes leads Quantum Immunologics in the pursuit of the research, development and implementation of new immunotherapy protocols for the treatment of cancer. Chuck Broes has initiated clinical trials that are currently underway and new patents have been filed providing the company with a pipeline for ongoing improvements in cancer treatment.
According to Chuck Broes, Quantum Immunologics was formed for the sole purpose of developing, implementing and distributing new advanced levels of proprietary therapeutic treatments and diagnostic tools. Chuck Broes presents Quantum Immunologics’ mission as fostering the development and support for these and other technologies that are complementary to its current portfolio of patented intellectual properties that are focused on immune diseases and disorders.
To contact Chuck Broes or for more information about Quantum Immunologics please visit: www.quantumimmunologics.com or call 866-213-4594.
Company Contact Information
Quantum Immunologics
Chuck Broes
1881 W. Kennedy Blvd, Suite 100, Tampa, FL
33606
Phone : 866-213-4594
|
